GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% logo.

Gammagard Liquid has been part of the
Takeda family of IG therapies since 2005*

*Approved for PI in 2005, MMN in 2012, and CIDP in 2024.


GAMMAGARD LIQUID is a ready-to-use liquid medicine that is given in a vein (intravenously) or under the skin (subcutaneously) to treat Primary Immunodeficiency (PI) in people 2 years and older, given in a vein to treat Multifocal Motor Neuropathy (MMN) in adults, and given in a vein to treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in adults.

 

Learn more about GAMMAGARD LIQUID for

 

Scroll to see more

GAMMAGARD LIQUID: an established IG with a
long-standing history in primary immunodeficiency (PI)

World icon.

16,000+

people infused
GAMMAGARD LIQUID
in 2023‡

20 years icon.

20+

years of real-world
experience§

IVIG bag icon.

2,253,688

infusions‡

†Marketing Research Bureau (MRB) database of total IG Units prescribed (2006-2023).

‡Calculations based on units of GAMMAGARD LIQUID sold from 2006-2023, assuming an average utilization of 450 g/yr/patient and 12 infusions/yr/patient.

§Approved for PI in 2005

Made with your needs in mind

Not all IG are the same. GAMMAGARD LIQUID has a different formula.

No added sugar icon.

No added sugars,
sucrose or glucose

No added sodium icon.

No added
sodium

No added preservatives icon.

No added
preservatives

No stabilizers icon.

No proline
stabilizers

GAMMAGARD LIQUID is also stabilized and buffered with glycine.

What is PI?

What is MMN?

What is CIDP?